PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar rhabdomyosarcoma

Cancer Research

Volumn 75, Issue 1, 2015, Pages 98-110

  Thalhammer, Verena ^a   Lopez Garcia, Laura A ^a   Herrero Martin, David ^a   Hecker, Regina ^a   Laubscher, Dominik ^a   Gierisch, Maria E ^a   Wachtel, Marco ^a   Bode, Peter ^b   Nanni, Paolo ^c   Blank, Bernd ^d   Koscielniak, Ewa ^d   Schäfer, Beat W ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c FUNCTIONAL GENOMICS CENTER ZURICH   (Switzerland)

^d OLGAHOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; POLO LIKE KINASE 1; PROTEASOME; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; CELL CYCLE PROTEIN; MOLECULAR LIBRARY; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3-FOXO1A FUSION PROTEIN, HUMAN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; EVENT FREE SURVIVAL; GENE EXPRESSION; OVERALL SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RHABDOMYOSARCOMA; TUMOR BIOPSY; ANIMAL; ANTAGONISTS AND INHIBITORS; FEMALE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; MOLECULAR LIBRARY; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RHABDOMYOSARCOMA, ALVEOLAR; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TRANSFECTION;

EID: 84920528091     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1246     Document Type: Article

References (52)

1. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the intergroup rhabdomyosarcoma study IV. J Clin Oncol 2003;21:78-84.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
3. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013;24:710-24.
4. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014;4:216-31.
5. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002;20:2672-9.
6. Linardic CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 2008;270:10-8.
7. Olanich ME, Barr FG. A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma. Expert Opin Ther Targets 2013;17:607-23.
8. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010;70:6497-508.
9. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;66:6936-46.
10. Ebauer M, Wachtel M, Niggli FK, Schafer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007;26:7267-81.
11. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998;58:5009-13.
12. Lae M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007;212: 143-51.
13. Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004;64:5539-45.
14. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, Schafer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 1996;93:13164-9.
15. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E, et al. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res 2000;60:5803-14.
16. Stegmaier S, Poremba C, Schaefer KL, Leuschner I, Kazanowska B, Bekassy AN, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer 2011;57:406-14.
17. Missiaglia E, Williamson D, Chisholm J,Wirapati P, Pierron G, Petel F, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012;30:1670-7.
18. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1997;94:8047-51.
19. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1996;93:5455-9.
20. Bennicelli JL, Advani S, Schafer BW, Barr FG. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 1999;18:4348-56.
21. Miller PJ, Hollenbach AD. The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 2007;1770:1450-8.
22. del Peso L, Gonzalez VM, Hernandez R, Barr FG, Nunez G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 1999;18:7328-33.
23. Amstutz R, Wachtel M, Troxler H, Kleinert P, Ebauer M, Haneke T, et al. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res 2008;68:3767-76.
24. Liu L, Wu J, Ong SS, Chen T. Cyclin-dependent kinase 4 phosphorylates and positively regulates PAX3-FOXO1 in human alveolar rhabdomyosarcoma cells. PLoS ONE 2013;8:e58193.
25. Jothi M, Mal M, Keller C, Mal AK. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol Cancer Ther 2013;12:2663-74.
26. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-30.
27. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A 1994;91:1736-40.
28. Cholewa BD, Liu X, Ahmad N. The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res 2013;73:6848-55.
29. Guenther MK, Graab U, Fulda S. Synthetic lethal interaction between PI3K/ Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett 2013;337:200-9.
30. Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res 2013;19:5940-51.
31. Scholl FA, Betts DR, Niggli FK, Schafer BW.Molecular features of a human rhabdomyosarcoma cell linewith spontaneous metastatic progression. Br J Cancer 2000;82:1239-45.
32. Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol 2013;3:183.
33. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008;365:568-74.
34. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22.
35. Grass B, Wachtel M, Behnke S, Leuschner I, Niggli FK, Schafer BW. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009;54:873-9.
36. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006;24:816-22.
37. Marshall AD, van der Ent MA, Grosveld GC. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma. Mol Carcinog 2012;51:807-15.
38. Thuault S, Hayashi S, Lagirand-Cantaloube J, Plutoni C, Comunale F, Delattre O, et al. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness. Oncogene 2013;32: 1876-87.
39. De Pitta C, Tombolan L, Albiero G, Sartori F, Romualdi C, Jurman G, et al. Gene expression profiling identifi es potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 2006;118:2772-81.
40. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-15.
41. Kettenbach AN, Wang T, Faherty BK, Madden DR, Knapp S, Bailey-Kellogg C, et al. Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem Biol 2012;19:608-18.
42. Liu Z, Ren J, Cao J, He J, Yao X, Jin C, et al. Systematic analysis of the Plk-mediated phosphoregulation in eukaryotes. Brief Bioinform 2013;14:344-60.
43. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
44. Bakay M, Wang Z, Melcon G, Schiltz L, Xuan J, Zhao P, et al. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006;129:996-1013.
45. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009;8:3024-35.
46. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic pro file and broad antitumor activity. Clin Cancer Res 2009;15: 3094-102.
47. Rena G, Woods YL, Prescott AR, Peggie M, Unterman TG, Williams MR, et al. Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. Embo J 2002;21:2263-71.
48. Yuan C, Wang L, Zhou L, Fu Z. The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation. Cell Cycle 2014;13:807-819.
49. Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 2013;3:1156-71.
50. Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, et al. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet 2014;10:e1004107.
51. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, et al. Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the pediatric preclinical testing program. Pediatr Blood Cancer 2014;61:158-64.
52. Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRbeta reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 2014;111:6383-8.